09:03 AM EDT, 05/01/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) on Friday said it renamed its oral semaglutide pill Rybelsus to Ozempic for easier recognition among diabetes patients and health workers.

Starting May 4, the relaunched and reformulated Ozempic tablets with 1.5-milligram, 4-milligram, and 9-milligram doses will be available in the US for adults with type 2 diabetes.

The Danish drugmaker said it will continue to market Rybelsus outside the US.

Novo Nordisk ADR

Senast

43,73

1 dag %

3,58%

1 dag

1 mån

1 år

Novo Nordisk B

Senast

278,00

1 dag %

2,11%
Marknadsöversikt

1 DAG %

Senast

1 mån